Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 17, 2025 07:07 ET | Source: Pluristyx, Inc.

Pluristyx Collaborates with Breakthrough T1D to Make “Immune-Cloaked” and Safety Switch-Enabled Allogeneic Cell Line for Type 1 Diabetes Therapies

Pluristyx and Breakthrough T1D partner to engineer an immune-cloaked, safety-enabled iPSC line to advance universal islet therapies for type 1 diabetes.
November 05, 2025 07:02 ET | Source: Pluristyx, Inc.

Pluristyx Executes Key Commercial Clinical Use Licenses for iPSC Portfolio, Enabling Novel Therapies for Regenerative Medicine and Neurological Disease Therapeutics

Pluristyx signs key clinical use licenses for its iPSC platform, enabling new regenerative and neurological disease therapies.